Improvement of Left Ventricular Global Longitudinal Strain after 6-Month Therapy with GLP-1RAs Semaglutide and Dulaglutide in Type 2 Diabetes Mellitus: A Pilot Study

• Published in: Journal of clinical medicine 2023-02, Vol.12 (4), p.1586
• Main Authors: Basile, Paolo, Guaricci, Andrea Igoren, Piazzolla, Giuseppina, Volpe, Sara, Vozza, Alfredo, Benedetto, Marina, Carella, Maria Cristina, Santoro, Daniela, Monitillo, Francesco, Baggiano, Andrea, Mushtaq, Saima, Fusini, Laura, Fazzari, Fabio, Forleo, Cinzia, Ribecco, Nunziata, Pontone, Gianluca, Sabbà, Carlo, Ciccone, Marco Matteo
• Format: Article
• Language: English
• Subjects: Antidiabetics; Automation; Blood pressure; Cardiovascular disease; Cardiovascular diseases; Clinical medicine; Diabetes; Drug therapy; Heart rate; Hypertension; Laboratories; Patient outcomes; Patients; Prescription drugs; Prevention; Pulmonary arteries; Risk factors; Society; Statistical analysis; Type 2 diabetes; Values; Variables
• ISSN: 2077-0383; 2077-0383
• DOI: 10.3390/jcm12041586

(1) Background: Glucagone-Like Peptide-1 Receptor Agonists (GLP-1 RAs) (GLP-1 RAs) are incretine-based medications recommended in the treatment of type 2 Diabetes Mellitus (DM2) with atherosclerotic cardiovascular disease (ASCVD) or high or very high cardiovascular (CV) risk. However, knowledge of the direct mechanism of GLP-1 RAs on cardiac function is modest and not yet fully elucidated. Left ventricular (LV) Global Longitudinal Strain (GLS) with Speckle Tracking Echocardiography (STE) represents an innovative technique for the evaluation of myocardial contractility. (2) Methods: an observational, perspective, monocentric study was conducted in a cohort of 22 consecutive patients with DM2 and ASCVD or high/very high CV risk, enrolled between December 2019 and March 2020 and treated with GLP-1 RAs dulaglutide or semaglutide. The echocardiographic parameters of diastolic and systolic function were recorded at baseline and after six months of treatment. (3) Results: the mean age of the sample was 65 ± 10 years with a prevalence of the male sex (64%). A significant improvement in the LV GLS (mean difference: -1.4 ± 1.1%; value < 0.001) was observed after six months of treatment with GLP-1 RAs dulaglutide or semaglutide. No relevant changes were seen in the other echocardiographic parameters. (4) Conclusions: six months of treatment with GLP-1 RAs dulaglutide or semaglutide leads to an improvement in the LV GLS in subjects with DM2 with and high/very high risk for ASCVD or with ASCVD. Further studies on larger populations and with a longer follow-up are warranted to confirm these preliminary results.